Background: Hepatitis A vaccine is safe and achieves good seroconversion rates in liver (LTX) and renal (RTX) transplant recipients.
Methods: A study was performed to determine the anti-hepatitis A virus (HAV) antibody decline in LTX and RTX patients, and in healthy controls who have been immunized with two doses of hepatitis A vaccine.
Results: LTX and RTX patients had a satisfactory seroconversion rate after complete immunisation. However, 2 years later they had experienced a much more rapid antibody decline than controls, and only 59% of LTX and 26% of RTX seroconverters showed titres above the cut-off level defined as protective.
Conclusions: Patients on immunosuppressive therapy may not be adequately protected against hepatitis A a few years after vaccination and alternative vaccination schemes may have to be considered.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00007890-200102150-00023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Portable pH meter-based competitive immunoassay of E-selectin using urease-encapsulated metal-organic frameworks.
Talanta
January 2025
Key Laboratory of Chemical Biology and Traditional Chinese Medicine Research (Ministry of Education of China), College of Chemistry and Chemical Engineering, Hunan Normal University, Changsha, 410081, PR China. Electronic address:
E-selectin (CD62E) is an adhesion molecule expressed on the surface of endothelial cells (ECs) and its level increases significantly upon the stimulation of ECs by inflammatory factors. Quantitative analysis of CD62E is of great importance to early diagnosis and treatment of vascular diseases and hypertension. A new method for the determination of CD62E was developed using a portable pH meter in this work.
View Article and Find Full Text PDFExploring the Pathophysiology, Diagnosis, and Treatment Options of Multiple Sclerosis.
J Integr Neurosci
January 2025
Department of Ophthalmology, University Hospital of Udine, 33100 Udine, Italy.
The complicated neurological syndrome known as multiple sclerosis (MS) is typified by demyelination, inflammation, and neurodegeneration in the central nervous system (CNS). Managing this crippling illness requires an understanding of the complex interactions between neurophysiological systems, diagnostic techniques, and therapeutic methods. A complex series of processes, including immunological dysregulation, inflammation, and neurodegeneration, are involved in the pathogenesis of MS.
View Article and Find Full Text PDFCharacterization of Vaccine-Enhanced Humoral Immune Responses Against Emergent SARS-CoV-2 Variants in a Convalescent Cohort.
Pathogens
January 2025
Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.
Vaccination of COVID-19-convalescent individuals may generate 'hybrid' immunity of enhanced magnitude, durability, and cross-reactive breadth. Our primary goal was to characterize hybrid antibody (Ab) responses in a patient cohort infected with ancestral Wuhan-Hu-1 virus and vaccinated between 6 and 10 months later with the Wuhan-Hu-1-based BNT162b2 mRNA vaccine. We were particularly interested in determining the efficacy of neutralizing Ab responses against subsequently emergent SARS-CoV-2 variants.
View Article and Find Full Text PDFFc-binding nanodisc restores antiviral efficacy of antibodies with reduced neutralizing effects against evolving SARS-CoV-2 variants.
J Nanobiotechnology
January 2025
Department of Integrative Biotechnology, College of Biotechnology and Bioengineering, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
Passive antibody therapies, typically administered via parenteral routes, have played a crucial role in the initial response to the COVID-19 pandemic. However, the ongoing evolution of SARS-CoV-2 has revealed significant limitations of this approach, primarily due to mutational escape and the inadequate delivery of antibodies to the upper respiratory tract. To overcome these challenges, we propose a novel prophylactic strategy involving the intranasal delivery of an antibody in combination with an Fc-binding nanodisc.
View Article and Find Full Text PDFLong-term antibody trajectories after PPSV23 in elderly: Results from a 4-year follow-up study.
Vaccine
January 2025
Beijing Center for Disease Prevention and Control, No. 16, Hepingli Middle Street, Dongcheng District, Beijing 100013, China. Electronic address:
Background: The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is recommended for standalone or sequential use in the elderly in many countries to prevent pneumococcal disease, making it crucial to assess vaccine response and long-term persistence.
Purpose: We aimed to describe the trajectories of circulating antibody levels to the PPSV23 in the elderly following immunization.
Methods: Eligible individuals aged 65 to 70 years were enrolled and vaccinated with one dose of PPSV23.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!